Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Abpro Holdings Inc (ABPWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ABPWW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -91.07% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.39 | 52 Weeks Range 0.01 - 0.18 | Updated Date 05/24/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1055.19% |
Management Effectiveness
Return on Assets (TTM) -33.51% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3717658 |
Shares Outstanding - | Shares Floating 3717658 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Abpro Holdings Inc
Company Overview
History and Background
Abpro Holdings Inc. is a biopharmaceutical company focused on developing antibody-based therapies for cancer and other diseases. Specific founding year and detailed milestones require further primary source verification. Public information on historical evolution is limited.
Core Business Areas
- Therapeutic Antibody Development: Development of novel antibody-based therapeutics targeting cancer, autoimmune, and infectious diseases. Focus on utilizing proprietary DiversImmuneu2122 platform.
Leadership and Structure
Leadership details and organizational structure require further research. Information is generally available on their website and through SEC filings.
Top Products and Market Share
Key Offerings
- ABP-201: An anti-CD137 agonist antibody being developed for cancer immunotherapy. Clinical trial status and specific market share data not publicly available. Competitors include companies developing similar CD137 agonists.
- ABP-300: Program targeting SARS-CoV-2. Market share and impact not determinable. Competition from established COVID-19 vaccine and therapeutic developers.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. It is driven by unmet medical needs and technological advancements.
Positioning
Abpro is a smaller player in the biopharmaceutical industry, focusing on antibody-based therapies. Its competitive advantage relies on its DiversImmuneu2122 platform and novel targets.
Total Addressable Market (TAM)
The TAM for antibody therapies in oncology and autoimmune diseases is substantial, estimated at hundreds of billions of dollars. Abpro's positioning depends on the success of its clinical trials and ability to secure partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary DiversImmuneu2122 platform
- Focus on novel antibody therapeutics
- Pipeline of drug candidates
- Potential for partnerships and collaborations
Weaknesses
- Limited financial resources
- Early-stage development programs
- High risk of clinical trial failure
- Dependence on partnerships for funding
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
- Advancements in antibody engineering
Threats
- Competition from established biopharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent disputes
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- BMY
- PFE
Competitive Landscape
Abpro faces significant competition from larger, more established biopharmaceutical companies. Its success hinges on its proprietary technology and clinical trial outcomes.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on past financial performance. Information not readily available.
Future Projections: Future growth projections rely on clinical trial success and market adoption, which are uncertain. Requires analyst reports for specific forecasts.
Recent Initiatives: Recent initiatives require monitoring company announcements and press releases.
Summary
Abpro Holdings Inc. is an early-stage biopharmaceutical company with potential in antibody-based therapies, particularly cancer. Its DiversImmune platform presents opportunities for novel drug development. However, it faces financial constraints and high clinical trial risks. Strategic partnerships are crucial for its future success, and the company needs to be able to bring its ideas successfully to market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Press Releases
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biopharmaceutical industry is subject to significant risk and uncertainty. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abpro Holdings Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2022-03-07 | CEO & Chairman of the Board Mr. Jin Wook Suk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://abpro.co |
Full time employees 6 | Website https://abpro.co | ||
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.